Professor | Su-Ling Liu | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Su-Ling Liu
Contact Information	suling@fudan.edu.cn
Language ability	English, Chinese
Province	Shanghai

Upload Avatar (500 x 500)

Name

Su-Ling Liu

Contact Information

suling@fudan.edu.cn

Language ability

English, Chinese

Province

Shanghai

University/Lab Affiliation and Title	Fudan University
Faculty	Biomedical Sciences
Academic Background & Achievements	1997-2003 Ph.D.: Ohio State University, Department of Biology 1992-1997 Bachelor's: University of Science and Technology of China, Department of Biology 2021 Shanghai Leading Talent, Shanghai Municipal Party Committee and Shanghai Human Resources and Social Security Bureau 2020 Young and Middle-aged Leading Talent in Scientific and Technological Innovation, Ministry of Science and Technology 2020 Academic Leader of Shanghai Science and Technology Innovation Action Plan 2020 Fudan University 'Excellence 2025': Outstanding Talent 2019 Shanghai Medical Leading Talent, Shanghai Municipal Health Commission 2014 National Excellent Young Scientist Fund, National Natural Science Foundation of China 2012 Youth Project of Overseas High-level Talent Introduction Program, Central Organization Department
Work Experience	2016.12-Present - Fudan University - Professor, Biomedical Research Institute/Affiliated Cancer Hospital 2012.11-2016.11 - University of Science and Technology of China - Professor, School of Life Sciences 2010.10-2012.10 - University of Michigan - Research Assistant Professor 2006.10-2010.09 - University of Michigan - Assistant Researcher 2003.12-2006.09 - University of Michigan - Postdoctoral Researcher
Awards	2020 WuXi AppTec Life Chemistry Research Award 2018 China Young Scientist Award in Oncology, Chinese Anti-Cancer Association 2014 Sino-American Anti-Cancer Association - National Cancer Foundation Academic Award 2010 Susan G. Komen Scholar in Training Award, American Cancer Society 2006 Merck Scholar in Training Award, American Cancer Society

University/Lab Affiliation and Title

Fudan University

Faculty

Biomedical Sciences

Academic Background & Achievements

1997-2003 Ph.D.: Ohio State University, Department of Biology
1992-1997 Bachelor's: University of Science and Technology of China, Department of Biology
2021 Shanghai Leading Talent, Shanghai Municipal Party Committee and Shanghai Human Resources and Social Security Bureau
2020 Young and Middle-aged Leading Talent in Scientific and Technological Innovation, Ministry of Science and Technology
2020 Academic Leader of Shanghai Science and Technology Innovation Action Plan
2020 Fudan University 'Excellence 2025': Outstanding Talent
2019 Shanghai Medical Leading Talent, Shanghai Municipal Health Commission
2014 National Excellent Young Scientist Fund, National Natural Science Foundation of China
2012 Youth Project of Overseas High-level Talent Introduction Program, Central Organization Department

Work Experience

2016.12-Present - Fudan University - Professor, Biomedical Research Institute/Affiliated Cancer Hospital
2012.11-2016.11 - University of Science and Technology of China - Professor, School of Life Sciences
2010.10-2012.10 - University of Michigan - Research Assistant Professor
2006.10-2010.09 - University of Michigan - Assistant Researcher
2003.12-2006.09 - University of Michigan - Postdoctoral Researcher

Awards

2020 WuXi AppTec Life Chemistry Research Award
2018 China Young Scientist Award in Oncology, Chinese Anti-Cancer Association
2014 Sino-American Anti-Cancer Association - National Cancer Foundation Academic Award
2010 Susan G. Komen Scholar in Training Award, American Cancer Society
2006 Merck Scholar in Training Award, American Cancer Society

Areas of Focus	Heterogeneity and regulation of breast cancer stem cells and drug resistance Origin of breast cancer stem cells Interaction between tumor microenvironment and cancer stem cells Immune regulation of cancer stem cells New therapeutic strategies targeting cancer stem cells and drug development
Publications	Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization, Sheng, D., Ma, W., Zhang, R., Zhou, L., Deng, Q., Tu, J., Chen, W., Zhang, F., Gao, N., Dong, M., Wang, D., Li, F., Liu, Y., He, X., Duan, S., Zhang, L., Liu, T., Liu, S., 2022 Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity, Zhang, R.#, Tu, J.#, Liu, S., 2022 TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer, Xu, J., Yang, X., Deng, Q., Yang, C., Wang, D., Jiang, G., Yao, X., He, X., Ding, J., Qiang, J., Tu, J., Zhang, R., Lei, Q., Shao, Z-M., Bian, X., Hu, R., Zhang, L., Liu, S., 2021 ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression, Liu, C., Qiang, J., Deng, Q., Xia, J., Deng, L., Zhou, L., Wang, D., He, X., Liu, Y., Zhao, B., Lv, J., Yu, Z., Lei, Q., Shao, Z., Zhang, X., Zhang, L., Liu, S., 2021 Single-cell transcriptomics reveal the heterogeneity and dynamic of cancer stem-like cells during breast tumor progression, Jiang, G.#, Tu, J.#, Zhou, L.#, Dong, M., Fan, J., Chang, Z., Zhang, L., Bian, X., Liu, S., 2021 Cancer Stem Cells and Neovascularization, Li, F. #, Xu, J. #, Liu, S., 2021 Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity, Huang, Y.#, Wang, H., Hao, Y., Lin, H., Dong, M., Ye, J., Song, L., Wang, Y., Li, Q., Shan, B., Jiang, Y., Li, H., Shao, Z.M., Kroemer, G., Zhang, H., Bai, L., Jin, T., Wang, C., Ma, Y., Cai, Y., Ding, C., Liu, S.,Pan, Y., Jiang, W., Zhou R., 2020 UCP1 regulates ALDH-positive breast cancer stem cells through releasing the suppression of Snail on FBP1, Zhang, F. #, Liu, B., Deng, Q., Sheng, D., Xu, J., He, X., Zhang, L., Liu, S., 2020 Mechanistic insights of adipocyte metabolism in regulating breast cancer progression, Zhang, F. #, Liu, S., 2020 Interfering MSN-NONO complex activated CREB signaling serves a novel therapeutic strategy for triple-negative breast cancer, Qin, Y. #, Chen, W. #, Jiang, G., Zhou, L., Yang, X., Li, H., He, X., Wang, H., Zhou, Y., Huang, S., Liu, S., 2020 IL1R2 blockade suppresses breast tumorigenesis and progression by impairing USP15-dependent BMI1 stability, Zhang, L. #, Qiang, J. #, Yang, L. #, Wang, D., Adeel, R., He, X., Chen, W., Sheng , D., Zhou, L., Jiang, Y. Z., Li, T., Du, Y., Feng, J., Hu, X., Zhang, J., Hu, X. C., Shao, Z. M., Liu, S., 2020 NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer, Zhou， L. #, Wang, D. #, Sheng, D. #, Xu, J., Chen, W., Qin, Y., Du, R., Yang, X., He, X., Xie, N., Liu, S., Zhang, L., 2020 Membrane-bound TNF mediates microtubule-targeting chemotherapeutics-induced cancer cytolysis via juxtacrine inter-cancer-cell death signaling, Zhang, J., Yang, Y., Zhou, S., He, X., Cao, X., Wu, C., Hu, H., Qin, J., Wei, G., Wang, H., Liu, S., Sun, L., 2019 Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function, Jiang, G.#, Wang, X.#, Sheng, D., Zhou, L., Liu, Y., Xu, C., Liu, S. and Zhang, J., 2019 The endogenous retrovirus-derived long noncodingRNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation, Jin, X. #, Xu, X-E. # , Jiang, Y-Z. #, Liu, Y-R., Sun, W., Guo, Y-J., Ren, Y-X., Zuo, W-J., Hu, X., Huang, S-L., Shen, H-J., Lan, F., He, Y-F., Hu, G-H., Di, G-H., He, X-H., Li, D-Q., Liu, S., Yu, K-D.,, Shao, Z-M., 2019 Stress-induced epinephrine enhances lactate dehydrogenase A and promotes breast cancer stem-like cells, Cui, B., Luo, Y., Tian, P., Peng, F., Lu, J., Yang, Y., Su, Q., Liu, B., Yu, J., Luo, X., Yin, L., Cheng, W., An, F., He, B., Liang, D., Wu, S., Chu, P., Song, L., Liu, X., Luo, H., Xu, J., Pan, Y., Wang, Y., Li, D., Huang, P., Yang, Q., Zhang, L., Zhou, B.P., Liu, S., Xu, G.,Lam, E.W.-F., Kelley, K.W. and Liu, Q., 2019 Targeting the BRD4/FOXO3a/CDK6 axis Sensitizes AKT Inhibition in Luminal Breast Cancer, Liu, J., Duan, Z., Guo, W., Zeng, L., Wu, Y., Chen, Y., Tai, F., Wang, Y., Lin, Y., Zhang, Q., He, Y., Deng J., Stewart, R., Wang, C., Lin, P., Ghaffari, S., Evers, B.M., Liu, S., Zhou, M-M., Zhou, B., and Shi, J., 2018 miR-200c/141 regulates breast cancer stem cell heterogeneity via targeting HIPK1/β-catenin axis, Liu, B., Du, R., Zhou L., Xu, J., Chen, S., Chen, J., Yang, X., Liu, D-X., Shao, Z-M., Zhang, L., Yu, Z., Xie, N. , Guan, J-L., and Liu, S.*, 2018

Areas of Focus

Heterogeneity and regulation of breast cancer stem cells and drug resistance
Origin of breast cancer stem cells
Interaction between tumor microenvironment and cancer stem cells
Immune regulation of cancer stem cells
New therapeutic strategies targeting cancer stem cells and drug development

Publications

Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization, Sheng, D., Ma, W., Zhang, R., Zhou, L., Deng, Q., Tu, J., Chen, W., Zhang, F., Gao, N., Dong, M., Wang, D., Li, F., Liu, Y., He, X., Duan, S., Zhang, L., Liu, T.*, Liu, S.*, 2022
Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity, Zhang, R.#, Tu, J.#, Liu, S.*, 2022
TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer, Xu, J., Yang, X., Deng, Q., Yang, C., Wang, D., Jiang, G., Yao, X., He, X., Ding, J., Qiang, J., Tu, J., Zhang, R., Lei, Q., Shao, Z-M., Bian, X.*, Hu, R.*, Zhang, L.*, Liu, S.*, 2021
ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression, Liu, C., Qiang, J., Deng, Q., Xia, J., Deng, L., Zhou, L., Wang, D., He, X., Liu, Y., Zhao, B., Lv, J., Yu, Z., Lei, Q., Shao, Z.*, Zhang, X.*, Zhang, L.*, Liu, S.*, 2021
Single-cell transcriptomics reveal the heterogeneity and dynamic of cancer stem-like cells during breast tumor progression, Jiang, G.#, Tu, J.#, Zhou, L.#, Dong, M., Fan, J., Chang, Z., Zhang, L., Bian, X., Liu, S.*, 2021
Cancer Stem Cells and Neovascularization, Li, F. #, Xu, J. #, Liu, S.*, 2021
Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity, Huang, Y.#, Wang, H., Hao, Y., Lin, H., Dong, M., Ye, J., Song, L., Wang, Y., Li, Q., Shan, B., Jiang, Y., Li, H., Shao, Z.M., Kroemer, G., Zhang, H., Bai, L., Jin, T., Wang, C., Ma, Y., Cai, Y., Ding, C., Liu, S.*,Pan, Y.*, Jiang, W.*, Zhou R.*, 2020
UCP1 regulates ALDH-positive breast cancer stem cells through releasing the suppression of Snail on FBP1, Zhang, F. #, Liu, B., Deng, Q., Sheng, D., Xu, J., He, X., Zhang, L.*, Liu, S.*, 2020
Mechanistic insights of adipocyte metabolism in regulating breast cancer progression, Zhang, F. #, Liu, S.*, 2020
Interfering MSN-NONO complex activated CREB signaling serves a novel therapeutic strategy for triple-negative breast cancer, Qin, Y. #, Chen, W. #, Jiang, G., Zhou, L., Yang, X., Li, H., He, X., Wang, H., Zhou, Y., Huang, S., Liu, S.*, 2020
IL1R2 blockade suppresses breast tumorigenesis and progression by impairing USP15-dependent BMI1 stability, Zhang, L. #, Qiang, J. #, Yang, L. #, Wang, D., Adeel, R., He, X., Chen, W., Sheng , D., Zhou, L., Jiang, Y. Z., Li, T., Du, Y., Feng, J., Hu, X., Zhang, J., Hu, X. C., Shao, Z. M., Liu, S.*, 2020
NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer, Zhou， L. #, Wang, D. #, Sheng, D. #, Xu, J., Chen, W., Qin, Y., Du, R., Yang, X., He, X., Xie, N.*, Liu, S.*, Zhang, L.*, 2020
Membrane-bound TNF mediates microtubule-targeting chemotherapeutics-induced cancer cytolysis via juxtacrine inter-cancer-cell death signaling, Zhang, J., Yang, Y., Zhou, S., He, X., Cao, X., Wu, C., Hu, H., Qin, J., Wei, G., Wang, H., Liu, S.*, Sun, L.*, 2019
Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function, Jiang, G.#, Wang, X.#, Sheng, D., Zhou, L., Liu, Y., Xu, C., Liu, S.* and Zhang, J.*, 2019
The endogenous retrovirus-derived long noncodingRNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation, Jin, X. #, Xu, X-E. # *, Jiang, Y-Z. #, Liu, Y-R., Sun, W., Guo, Y-J., Ren, Y-X., Zuo, W-J., Hu, X., Huang, S-L., Shen, H-J., Lan, F., He, Y-F., Hu, G-H., Di, G-H., He, X-H., Li, D-Q., Liu, S.*, Yu, K-D.*,, Shao, Z-M.*, 2019
Stress-induced epinephrine enhances lactate dehydrogenase A and promotes breast cancer stem-like cells, Cui, B., Luo, Y., Tian, P., Peng, F., Lu, J., Yang, Y., Su, Q., Liu, B., Yu, J., Luo, X., Yin, L., Cheng, W., An, F., He, B., Liang, D., Wu, S., Chu, P., Song, L., Liu, X., Luo, H., Xu, J., Pan, Y., Wang, Y., Li, D., Huang, P., Yang, Q., Zhang, L., Zhou, B.P., Liu, S., Xu, G.,Lam, E.W.-F., Kelley, K.W. and Liu, Q.*, 2019
Targeting the BRD4/FOXO3a/CDK6 axis Sensitizes AKT Inhibition in Luminal Breast Cancer, Liu, J., Duan, Z., Guo, W., Zeng, L., Wu, Y., Chen, Y., Tai, F., Wang, Y., Lin, Y., Zhang, Q., He, Y., Deng J., Stewart, R., Wang, C., Lin, P., Ghaffari, S., Evers, B.M., Liu, S.*, Zhou, M-M.*, Zhou, B.*, and Shi, J.*, 2018
miR-200c/141 regulates breast cancer stem cell heterogeneity via targeting HIPK1/β-catenin axis, Liu, B., Du, R., Zhou L., Xu, J., Chen, S., Chen, J., Yang, X., Liu, D-X., Shao, Z-M., Zhang, L., Yu, Z., Xie, N. *, Guan, J-L.*, and Liu, S.*, 2018

Breast Cancer Stem Cells Heterogeneity Regulation Drug Resistance Tumor Microenvironment Immune Regulation Therapeutic Strategies Drug Development Cancer Research

Alastair Murchie - Fudan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us